Gadolinium-based contrast agents have been a cornerstone of magnetic resonance imaging since the late 1980s. By highlighting tissues with enhanced perfusion and permeability, they allow radiologists to spot tumors, map their boundaries, distinguish malignant from benign lesions, and monitor how treatment is working. But the agents carry baggage. In patients with severe kidney impairment they have been linked to nephrogenic systemic fibrosis, a rare but debilitating condition. Studies have also documented gadolinium deposits in the brain, bones, and other tissues even in people with normal kidney function, and the metal — which is not biodegradable — is increasingly turning up in rivers and groundwater after passing through wastewater treatment plants ill-equipped to remove it.

Those concerns have fueled a wave of research into AI methods that could reduce or eliminate the need for contrast injection altogether. One particularly ambitious approach is the synthesis of so-called T1ce images — T1-weighted scans taken after contrast administration — from a set of non-contrast scans such as T1, T2, and T2-FLAIR. Previous studies have generally judged these synthetic images by pixel-level similarity metrics like peak signal-to-noise ratio and structural similarity, or by qualitative review from radiologists. The GE HealthCare team, led by Dimosthenis Gkotsis and Hongxu Yang, argued that such measures are not enough. If synthetic images are ever to inform consequential decisions — tumor grading, radiotherapy planning, surgical margins, or distinguishing recurrence from radiation necrosis — they must be tested on the downstream tasks that actually matter.

The researchers built three state-of-the-art generative models trained on the publicly available BraTS19 dataset, which comprises 335 glioma patients, 259 with high-grade tumors and 76 with low-grade ones. The first model, called CoNeS, is a conditional neural field with shift modulation that encodes positional information to guide image generation. The second is a denoising diffusion probabilistic model, or DDPM, conditioned on the non-contrast sequences. The third was a hybrid that fed the CoNeS output into the diffusion model as an additional conditioning channel. The diffusion model also employed a coarse-to-fine sampling strategy that cut the effective number of sampling steps from 1,000 to 120, achieving roughly a ninefold speedup in image synthesis.

On standard image quality metrics, the hybrid CoNeS + DDPM model came out on top. On the test set it achieved a peak signal-to-noise ratio of 27.27 dB and a mean aggregate error of 6.81 percent on tumor-containing slices, comfortably ahead of the standalone models. But the picture grew murkier when the team zoomed into the tumors themselves. Within segmented tumor volumes, performance dropped for all models, and it was worst in the enhancing tumor region — precisely the tissue that gadolinium is supposed to illuminate. The mean error in that region reached nearly 18 percent even for the best model, suggesting that the intensity distributions of synthetic tumors are shifted relative to the real thing.

The segmentation experiments drove the point home. A 3D ResNet-10 UNet, trained from scratch under five-fold cross-validation, segmented whole tumors from synthetic images with Dice scores reaching 97 to 100 percent of what real contrast images achieved. But for the enhancing tumor component — the most clinically consequential target — Dice scores with synthetic inputs ranged from just 58 to 98 percent of the real-image benchmark, with the best synthetic configuration scoring 0.739 against 0.745 for real contrast images, and the pre-contrast baseline languishing at 0.434. Wilcoxon tests confirmed that the differences were statistically significant for nearly every comparison involving the enhancing region.

The grading task told a more nuanced story. The team evaluated two families of classifiers: a radiomics pipeline that extracted eighteen handcrafted features — from sphericity and entropy to texture measures like GLCM contrast — and fed them to a random forest, and a deep learning classifier that consumed the full brain volume end-to-end. Radiomics-based models achieved higher accuracy and area under the curve, with the real-contrast configuration reaching an AUC of 0.884, while deep learning models showed higher specificity and, in several synthetic settings, higher precision. Bootstrap analysis with 10,000 iterations revealed that neither family was uniformly superior, and — crucially — that no statistically significant AUC differences separated synthetic from real contrast images for either classifier family. In other words, the synthetic images largely preserved the information needed to distinguish high-grade from low-grade gliomas.

Yet the qualitative findings exposed the limits of those aggregate statistics. In several cases the synthetic images looked superb, with the generative models’ intrinsic denoising actually producing cleaner grey-white matter differentiation than the real scans. But in other cases the models hallucinated. A ring-enhancing pattern — a hallmark of high-grade glioma — appeared around a lesion that was in fact a low-grade tumor, a fabrication that could flip a grading decision. More alarming still, in one case a small contrast-enhancing region near a surgical resection border, the very finding that would determine whether a patient’s tumor had recurred and how treatment should proceed, was missed by every model. The anatomical structures — ventricles, midline, cortex — were faithfully reproduced, but the clinically decisive enhancement patterns were not.

The authors are careful about what their results permit. The study relied on a single, class-imbalanced public dataset, lacked external validation, and did not include a formal blinded review by radiologists. Genomic and histopathological information, increasingly central to glioma management, was absent from the synthesis inputs. Still, the conclusion is unambiguous: while AI-generated contrast-enhanced MRI has advanced dramatically — particularly through the marriage of conditional neural fields and diffusion models — the synthetic images cannot yet stand in for real gadolinium-enhanced scans in clinical practice. The researchers suggest that training on larger, more diverse datasets and incorporating additional input sequences such as diffusion-weighted and susceptibility-weighted imaging may close the gap. Until then, the contrast injection — with all its costs and controversies — remains irreplaceable at the moment when it matters most.

Subject of Research: Synthetic AI-generated contrast-enhanced MRI for glioma segmentation and grading

Article Title: Downstream evaluation of synthetic AI-generated T1-weighted contrast-enhanced MR images in glioma segmentation and grading

Article References: Gkotsis, D. E., Schwarz, A. J., Wolber, J., Ferenczi, L. M., & Yang, H. (2026). Downstream evaluation of synthetic AI-generated T1-weighted contrast-enhanced MR images in glioma segmentation and grading. Frontiers in Radiology, 6, Article 1931738. https://doi.org/10.3389/fradi.2026.1931738

Image Credits: AI Generated

DOI: 10.3389/fradi.2026.1931738

Keywords: glioma, MRI, contrast agents, gadolinium, deep learning, image synthesis, diffusion models, tumor segmentation, radiomics, brain tumors, medical imaging AI, BraTS dataset